Scientific publications

November 2023
CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer – Poster Number: 1361
SITC Poster
November 2023
PYX-102, an Anti-KLRG1 Antibody, Enhances Cytotoxic Activity of CD8 T cells from PBMC and Human Tumor Samples by Blocking the Interaction Between KLRG1 and Cadherins Poster Number: 572
SITC Poster
November 2023
First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of anti Siglec-15 PYX-106 in Subjects with Advanced Solid Tumors Poster Number: 756
SITC Poster
November 2023
A First-in-Human Phase 1 Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of the EDB+FN targeting ADC PYX-201 in Participants with Advanced Solid Tumors Poster Number: 762
SITC Poster
June 2023
A Phase 2 Trial with a Safety Lead-in to Evaluate the Addition of Sotigalimab, a CD40 Agonistic Monoclonal Antibody, to Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcoma
ASCO Poster
January 2023
Tissue Assessment of Therapeutic Responses to Neoadjuvant SCRT with and without Anit-CD40 Immunotherapy Sotigalimab (Sotiga) in Rectal Cancer
ASCO GI Poster
January 2023
Use of High-dimensional and Spatial Immune Profiling to Explore Sotigalimab (CD40 Agonist) Activation of Antigen Presenting Cells and T Cells in the Tumor Microenvironment in Patients with Esophageal/Gastroesophageal Junction Cancer
ASCO GI Poster
November 2022
Intratumoral Sotigalimab with Pembrolizumab Activates Antigen Presenting cells and Induces Local and Distant Anti Tumor Responses in First line Metastatic Melanoma: Results of a Phase I/II Study
SITC Presentation
September 2022
A Multicenter Phase 2 Study of Sotigalimab (CD40 Agonist) in Combination with Neoadjuvant Chemoradiation for Resectable Esophageal and Gastroesophageal Junction (GEJ) Cancers
ESMO Poster
June 2022
Distinct Biosignatures Associate with Survival After Chemoimmunotherapy in a Randomized, Three-arm Phase II Study in Patients with Metastatic Pancreatic Cancer
ASCO Presentation
321 Harrison Avenue
11th Floor, Suite 1
Boston, MA 02118
(617) 453-3596 | info@pyxisoncology.com
Pyxis Oncology
Linkedin-in